Hepatitis C Information Central


Discover the latest news about Hepatitis C infection, diagnosis, symptoms and treatments here at Hepatitis-Central.com.

Hep C information

News, Updates and Commentary

Free Newsletter
Hepatitis C Newsletter
We value your privacy. We will not rent your email to anyone.

HEPATITIS NEWS
The top stories compiled from over 5,500 sources, updated every 15 minutes

Report Assesses Blame in Hepatitis Cases
Health care workers at a Las Vegas endoscopy clinic linked to more than 80 cases of hepatitis C routinely mishandled injection equipment and medication vials and often failed to perform basic hand hygiene, according to a report from the Centers for

New treatment for hepatitis C
Oklahoma City: Researchers at the University of Oklahoma Health Sciences Center have found a new use for an old drug. Their findings appear online in the American Journal of Gastroenterology. The drug, Fluvastatin, has been approved since 1993 by the


UPDATES AND COMMENTARY RSS Feed

What You Must Know About Alcoholic Hepatitis
This much-needed synopsis of alcoholic hepatitis reminds us that you don't need to be a heavy drinker to suffer from this condition. Looking over the causes, risk factors and complications of alcoholic hepatitis will motivate anyone with liver concerns to...

15 Tips for Managing Interferon-Ribavirin Side Effects
Finding new ways to manage the side effects of Hepatitis C combination therapy adds to a person’s likelihood of conquering the virus....

New Mexico Offers Free Hepatitis C Hotline
Finally being recognized as the widespread, public health problem that it is, the New Mexico Department of Health has taken a giant step forward to help people with Hepatitis C. By launching a new, toll-free phone number, locals concerned about...

Rebetron

Important Safety Information

Anemia associated with therapy may exacerbate symptoms of coronary disease or deteriorate cardiac function. It is advised that complete blood counts (CBC) be obtained at baseline and at weeks 2 and 4 of therapy or more frequently if clinically indicated.

The most common adverse experiences associated with REBETRON Combination Therapy are:

"flu-like" symptoms, such as headache, fatigue, myalgia, and fever, which appear to decrease in severity as treatment continues. Severe psychiatric adverse events may manifest in patients receiving therapy with interferons, including INTRON A therapy. DEPRESSION AND SUICIDAL BEHAVIOR, INCLUDING SUICIDAL IDEATION, SUICIDAL ATTEMPTS, AND COMPLETED SUICIDES, MAY OCCUR.

Combination REBETOL/INTRON A therapy must not be used by women, or male partners of women, who are or may become pregnant during therapy and during the 6 months after stopping therapy.

Combination REBETOL/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Women of childbearing potential and men must use effective contraception (two reliable forms) during treatment and during the 6-month posttreatment follow-up period.

Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of REBETOL®. If pregnancy occurs in a patient or partner of a patient during treatment and during the 6 months after treatment stops, physicians are encouraged to report such cases by calling (800) 727-7064.


table Of Contents

Hepatitis Central

http://hepatitis-central.com

  Hep C information

Information at this website is for educational purposes only; statements about products and health conditions
have not been evaluated by the U.S. Food & Drug Administration.

©1994-2008 Hepatitis-Central.com
Updated 17 May 2008